Design Therapeutics, Inc. appointed David Shapiro, M.D., to its Board of Directors as a Class III director, effective March 31, 2026. Dr. Shapiro's term as a director will conclude at the company's 2027 annual meeting of stockholders. He was also appointed to the Nominating and Corporate Governance Committee of the Board. Dr. Shapiro will receive an annual cash retainer of $40,000 for Board service and an additional $5,000 for service on the Nominating Committee. He received an initial option grant to purchase 60,000 shares of common stock, vesting monthly over three years. Dr. Shapiro also received a prorated annual option grant to purchase 7,500 shares of common stock, vesting monthly over one year. The company and Dr. Shapiro entered into a standard indemnification agreement for directors and officers.